Method for testing and screening p38 map kinase modifiers
AssigneeThe Trustees of the University of Pennsylvania
InventorsGideon DREYFUSS, Mumtaz KASIM
Life of this patent
Estimating the term…
Abstract
This invention provides compounds that inhibit p38 mitogen-activated protein kinase. Moreover, the invention provides methods for testing a candidate compound for a p38 mitogen-activated protein kinase modifying activity by calculating the level of relocalization of an SMN complex component from the cytoplasm to the nucleus of a cell. Additionally, the invention provides a kit and a system for calculating the same.
Claims26
A method of decreasing p38 mitogen-activated protein kinase (MAPK) enzymatic activity in a cell, comprising the step of contacting said cell with a compound having a structure according to Formula (I):
- wherein R1 and R2 are independently substituted or unsubstituted, carbocyclic or heterocyclic aromatic ring;
- and
- X1 and X2 are independently O or S, thereby decreasing p38 mitogen-activated protein kinase (MAPK) enzymatic activity in a cell.
-6. (canceled)
A method of treating or inhibiting a disease in a subject, comprising administering to said subject a compound having a structure according to Formula (I):
- wherein R1 and R2 are independently substituted or unsubstituted, carbocyclic or heterocyclic aromatic ring;
- and
- X1 and X2 are independently O or S, wherein said disease is associated with elevated p38 mitogen-activated protein kinase (MAPK) enzymatic activity in a cell in said subject, thereby treating or inhibiting said disease in said subject.
-12. (canceled)
A method for testing a candidate compound for an ability to decrease p38 mitogen-activated protein kinase (MAPK) enzymatic activity in a cell, comprising the steps of:
- contacting said cell with said candidate compound and an additional compound, wherein said additional compound is capable of inhibiting protein synthesis in said cell and increasing an enzymatic activity of said p38 MAPK in said cell;
- and measuring the level of a SMN complex component in the cytoplasm of said cell, the nucleus of said cell, or a combination thereof, whereby, if said candidate compound increases the amount of the SMN complex component in said nucleus, decreases the amount of the SMN complex component in said cytoplasm, or a combination thereof, then said compound exhibits an ability to decrease MAPK enzymatic activity.
(canceled)
(canceled)
-58. (canceled)
A kit for testing a candidate compound for an ability to modify p38 mitogen-activated protein kinase (MAPK) enzymatic activity, in a cell, comprising an agent for measuring a relocation of an SMN complex component in said cell.
-72. (canceled)
Dependencies are inferred from the claim text.